1. Leif Thuesen

    0 Comments Leave a Comment

    1-17 of 17
    1. Mentioned In 17 Articles

    2. Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study

      Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study
      Aims To investigate the incidence of incomplete stent apposition and to explore the impact of the presence of thrombus and protruding plaque after stent implantation on neointima formation at follow-up in ST-segment elevation myocardial infarction (STEMI) patients with serial optical frequency domain imaging (OFDI) investigations. Methods and results In a multi-centre study, 141 patients with ST elevation myocardial infarction 12 h from onset were randomized to either PPCI with thrombectomy ...
      Read Full Article
    3. Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study—TROFI trial

      Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study—TROFI trial
      Aims Primary percutaneous coronary intervention (PPCI) with thrombectomy (TB) seems to reduce the thrombus burden, resulting in a larger flow area as measured with optical frequency domain imaging (OFDI). Methods and results In a multi-centre study, 141 patients with ST elevation myocardial infarction 12 h from onset were randomized to either PPCI with TB using an Eliminate catheter (TB: n = 71) or without TB (non-TB: n = 70), having operators blinded ...
      Read Full Article
    4. First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

      First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study
      ...oshinobu Onuma, MD, 4. Robert-Jan van Geuns, MD, PhD, 5. Bernard de Bruyne, MD, PhD, 6. Dariusz Dudek, MD, 7. Leif Thuesen, MD, 8. Pieter C. Smits, MD, PhD, 9. Bernard Chevalier, MD, 10. Dougal McClean, MBChB, 11. Jacque...
      Read Full Article
    5. Differences in Neointimal Thickness Between the Adluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable Scaffold: Evidence In Vivo About the Abluminal Healing Process

      Differences in Neointimal Thickness Between the Adluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable Scaffold: Evidence In Vivo About the Abluminal Healing Process
      ... PhD*, Frank Gijsen, MSc, PhD, Evelyn Regar, MD, PhD*, Jolanda Wentzel, MSc, PhD, Bernard de Bruyne, MD, PhD, Leif Thuesen, MD, John Ormiston, MD||, Dougal R. McClean, MD¶, Stephan Windecker, MD#, Bernard Chevalier, MD**...
      Read Full Article
    6. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?

      Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?
      ...ia-Garcia^a^, ^b^, ^c, Jung Ho Heo^a, Vasim Farooq^a, Chrysafios Girasis^a, Robert-Jan van Geuns^a, Leif Thuesen^d, Dougal McClean^e, Bernard Chevalier^f, Stephan Windecker^g, Jacques Koolen^h, Richard Ra...
      Read Full Article
    7. Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial

      Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial
      Aims: To analyse and to compare the changes in the various optical coherence tomography (OCT), echo-genicity intravascular ultrasound virtual histology (VH) of the everolimus-eluting bioresorbable scaffold (ABSORB) degradation parameters during the first 12 months after ASOERB implantation.
      Read Full Article
    8. Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography

      Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography
      ...e Brugaletta, MD*, Vasim Farooq, MBChB*, Yoshinobu Onuma, MD*, Roberto Diletti, MD*, Stephan Windecker, MD||, Leif Thuesen, MD¶, Dougal McClean, MD#, Jacques Koolen, MD, PhD, Robert Whitbourn, MD, Dariusz Dudek, MD, Piet...
      Read Full Article
    9. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study

      Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study
      Aims: Bioresorbable vascular scaffolds (BVS) present different mechanical properties as compared to metallic platform stents. Therefore, the standard procedural technique to achieve appropriate deployment may differ. Methods and results: Fifty-two lesions treated with 3x18 mm BVS were imaged with optical coherence tomography (OCT) post-implantation and screened for parameters suggestion non-optimal deployment.
      Read Full Article
    10. Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes

      Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes
      Objectives The aim of this study was to demonstrate that the prevention of early scaffold area shrinkage of the ABSORB BVS (Rev.1.1, Abbott Vascular, Santa Clara, California) was sustained and not simply delayed by a few months. Background With improved scaffold design and modified manufacturing process of its polymer, the second iteration of ABSORB (BVS 1.1) has improved performance to prevent a scaffold area reduction at 6 ...
      Read Full Article
    11. Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography

      Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography
      ...ore Brugaletta, MD*, Vasim Farooq, MBChB*, Roberto Diletti, MD*, Yoshinobu Onuma, MD*, Stephan Windecker, MD, Leif Thuesen, MD, Dougal McClean, MD, Jacques Koolen, MD, PhD||, Robert Whitbourn, MD¶, Dariusz Dudek, MD#, Pi...
      Read Full Article
    12. Terumo Europe N.V. announces the initiation of OCT Cardiovascular Study

      Terumo Europe N.V. announces the initiation of OCT Cardiovascular Study
      ... STEMI study that enrolled 249 STEMI patients and reported 4.4% of target lesion failure at 12 months.   Dr Leif Thuesen, a Principal Investigator of University Hospital Skejby, Aarhus, Denmark said: I am excited with ...
      Read Full Article
    13. Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes

      Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes
      ...uma, MD*; John A. Ormiston, MBChB, PhD; Bernard de Bruyne, MD, PhD; Evelyn Regar, MD, PhD; Dariusz Dudek, MD; Leif Thuesen, MD; Pieter C. Smits, MD, PhD; Bernard Chevalier, MD; Dougal McClean, MD; Jacques Koolen, MD, PhD...
      Read Full Article
    14. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.

      Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
      Aims: Multimodality imaging of the first-in-man trial using a fully resorbable everolimus-eluting scaffold (BVS, Abbott Vascular, Santa Clara, CA, USA) demonstrated at two years the bioresorption of the device while preventing restenosis. Nevertheless, the long-term safety and efficacy of this novel therapy remain to be documented. Methods and results: The ABSORB trial completed in July 2006 at four clinical sites in Europe and New Zealand the enrolment of 30 patients ...
      Read Full Article
    15. 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side Branches by Bioresorbable Vascular Scaffolds: A Proposal for Classification

      3-Dimensional Optical Coherence Tomography Assessment of Jailed Side Branches by Bioresorbable Vascular Scaffolds: A Proposal for Classification
      ..., Héctor M. García-García, MD, PhD*, Evelyn Regar, MD, PhD*, Joanna J. Wykrzykowska, MD*, Jacques Koolen, MD, Leif Thuesen, MD, Stefan Windecker, MD, Robert Whitbourn, MD||, Dougal R. McClean, MD¶, John A. Ormiston, MD#,...
      Read Full Article
    16. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (absorb): a prospective open-label trial.

      BACKGROUND: A fully bioabsorbable drug-eluting coronary stent that scaffolds the vessel wall when needed and then disappears once the acute recoil and constrictive remodelling processes have subsided has theoretical advantages. The bioasorbable everolimus-eluting stent (BVS) has a backbone of poly-L-lactic acid that provides the support and a coating of poly-D,L-lactic acid that contains and controls the release of the antiproliferative agent everolimus. We assessed the feasibility and safety of ...
      Read Full Article
    17. 1-17 of 17
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Leif Thuesen

    Leif Thuesen

    Leif Thuesen is with the Department of Interventional Cardiology at Aarhus University Hospital in Denmark.